Alchemia to Present at Cowen and Company 31st Annual Health Care Conference
March 04 2011 - 12:57PM
Business Wire
Alchemia Limited (ASX: ACL) announced today that Pete Smith,
Chief Executive Officer, is scheduled to present a corporate update
at the Cowen and Company 31st Annual Health Care Conference at 4:45
p.m. EST on Monday, March 7, 2011. The presentation will provide an
update on the approval process for the Company’s generic
fondaparinux product and the status of the pivotal Phase III study
of HA-Irinotecan in metastatic colorectal cancer.
About Alchemia:
The Company’s lead program is fondaparinux (a generic version of
GlaxoSmithKline’s Arixtra®, a synthetic anticoagulant mainly used
for the prevention of deep vein thrombosis). The ANDA for generic
fondaparinux was filed for approval with the US FDA in March 2009
and approval is pending. It is partnered with Dr Reddy’s
Laboratories for global manufacturing and marketing.
Alchemia’s pipeline of assets is built on two platform
technologies: HyACT® (targeted cancer delivery) and VAST® (drug
discovery). The primary objective of the HyACT® technology is to
develop a new generation of anti-cancer drugs which demonstrate
better efficacy. The lead product from the HyACT® platform is
HA-Irinotecan for which a phase III clinical trial in metastatic
colorectal cancer is ready to commence recruitment. In addition to
HA-Irinotecan, Alchemia has successfully taken two other
anti-cancer products HA-Doxorubicin (doxorubicin and hyaluronic
acid) and HA-Fluorouracil (5-fluorouracil and hyaluronic acid) into
successful Phase I clinical testing and they continue to
development on five other HyACT® drugs.
Australian Clinical Labs (ASX:ACL)
Historical Stock Chart
From May 2024 to Jun 2024
Australian Clinical Labs (ASX:ACL)
Historical Stock Chart
From Jun 2023 to Jun 2024
